GlassScriptPhysician profile
Annalisa B Perez
NPI 1518084862
$3,516.98
in general payments reported to CMS, 2019-2025
25 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $123 · 2021: $499 · 2022: $366 · 2023: $534 · 2024: $610 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.01 |
| Education | $123.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $393.32 | 2020-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $346.77 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $298.16 | 2023-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $254.04 | 2019-2025 | Soliris, Ultomiris |
| Amgen INC. | $219.25 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $215.58 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $186.60 | 2021-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $176.97 | 2021-2024 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $170.41 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $165.94 | 2021-2025 | Farxiga, Breztri |
| Fresenius USA Marketing, INC. | $155.66 | 2019-2025 | Velphoro |
| Mallinckrodt Hospital Products INC. | $145.28 | 2022-2023 | Acthar |
| Genzyme Corporation | $118.34 | 2025 | |
| Novartis Pharmaceuticals Corporation | $109.51 | 2024-2025 | |
| Horizon Therapeutics Plc | $106.62 | 2023 | Krystexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $85.39 | 2024 | Briviact |
| Travere Therapeutics, INC. | $71.70 | 2023-2024 | |
| Novo Nordisk INC | $60.20 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.12 | 2025 | Jardiance |
| Lilly USA, LLC | $52.19 | 2025 | Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $44.60 | 2022-2024 | Benlysta |
| Xeris Pharmaceuticals, INC. | $25.98 | 2025 | Gvoke Hypopen |
| Abbvie INC. | $20.68 | 2024 | |
| Octapharma USA, INC. | $20.34 | 2024 | Octagam Immune Globulin (Human) |
| Scpharmaceuticals INC. | $16.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annalisa Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.